ArticleDigestive diseases and sciences2026
Reassessing Vonoprazan for Endoscopy-Negative Reflux Disease: A Systematic Review and Meta-Analysis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autoimmune Hepatitis-Associated Hepatocellular Carcinoma: Clarifying the Evidence-A Reply.Digestive diseases and sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-erosive reflux disease (NERD) is characterized by reflux without esophageal erosions. Vonoprazan, a potassium-competitive acid blocker, is recommended for patients with erosive esophagitis (EE). However, its role in NERD, remains limited. We conducted a systematic review and meta-analysis to assess its efficacy in patients with NERD.
methodsA systematic literature search was conducted, on MEDLINE, Embase and Cochrane Library until January 25, 2025, to identify all randomized controlled trials (RCTs) comparing Vonoprazan to placebo in patients with NERD. Binary and continuous outcomes were pooled using risk ratios (RRs), and standardized mean differences (SMDs), respectively, along with their 95% confidence intervals (CIs).
resultsFour RCTs with a total of 2540 patients (50.3% females) were included. Vonoprazan 10 mg was comparable to placebo in terms of mean proportion of days without heartburn (SMD: 0.12; 95% CI - 0.04-0.29, p = 0.14), mean severity score of heartburn (SMD: 0.01; 95% CI - 0.15-0.17, p = 0.94), treatment-related adverse events (RR: 0.93; 95% CI: 0.71-1.20, p = 0.568), and serious adverse events (RR: 1.46; 95% CI 0.23-9.23, p = 0.689). Vonoprazan 20 mg was superior to placebo in terms of mean proportion of days without heartburn (SMD: 0.13; 95% CI 0.01-0.24 p = 0.03), with comparable results for mean severity score of heartburn (SMD: - 0.03; 95% CI - 0.15-0.08 p = 0.56), treatment-related adverse events (RR: 1.11; 95% CI 0.52-2.36 p = 0.785), and serious adverse events (RR: 6.03; 95% CI 0.73-50.10 p = 0.096).
conclusionVonoprazan 10 mg showed no benefit over placebo in NERD. The 20 mg dose modestly increased heartburn-free days with similar safety, suggesting potential efficacy.
Indexed as
Identifiers
40965559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.